A new peer-reviewed publication from the Alzheimer’s Drug Discovery Foundation (ADDF) and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) offers strategic insight on how philanthropy, industry and government organizations can advance repurposing of U.S. Food and Drug Administration (FDA)-approved drugs for the treatment of neurodegenerative diseases. The paper, published in the Annals of Clinical and Translational Neurology, was produced in collaboration with experts from these sectors and highlights the unique challenges and lack of commercial incentives for testing approved drugs in new disease indications, like Alzheimer’s or Parkinson’s disease, where they might be beneficial.
The Alzheimer’s Drug Discovery Foundation (ADDF) and OnDeckBiotech announced today a strategic partnership to provide a new platform technology for ADDF ACCESS. ADDF ACCESS is an open access database that provides a network of contract research organizations (CROs), drug development consultants and educational resources focused for diseases of the central nervous system (CNS). By leveraging OnDeckBiotech’s cutting-edge technology, ADDF ACCESS will increase the efficiency of contracting drug development services by scientists in academia and small biotechnology companies.
Researchers from The Ohio State (Columbus) and Emory (Atlanta) Universities will be the first recipients of drug discovery funding and innovation support from a new partnership between the Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute (HDI) at University Hospitals Case Medical Center. The organizations will leverage their combined expertise and resources to advance highly promising Alzheimer's disease drug discovery projects conducted in academic medical institutions nationwide.
Drug Could Be the First to Slow the Progression of Alzheimer’s Disease
The Alzheimer’s Drug Discovery Foundation (ADDF) announced today that it raised more than $1.1 million in support of a clinical trial to test an existing drug for the treatment of Alzheimer’s disease. The $1.1 million was generated during the “Fund a Scientist” auction at its Eighth Annual Connoisseur’s Dinner on May 1, 2014, and awarded to Jeffrey Cummings, MD, director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio. Dr. Cummings will investigate rasagiline, an FDA-approved treatment for Parkinson’s disease with the potential to be the first drug to slow the course of Alzheimer’s disease.
Resource Will Provide Comprehensive Overview of the Science for Prevention Therapies
The Alzheimer’s Drug Discovery Foundation (ADDF) announced today the launch of Cognitive Vitality, a new online resource developed to provide a comprehensive and credible overview and analysis of the science for specific strategies to prevent Alzheimer’s and related dementias. The resource showcases the strength of the science for and against prevention strategies related to nutrition and the management of other diseases, to enable people to make informed decisions in protecting their brain from cognitive decline, Alzheimer’s and other dementias.
Outcomes Could Lead to Development of New and Cost-Effective Tools for Early Detection
The Alzheimer’s Disease and Dementia Initiative (ADDI) at the New York Academy of Sciences (the Academy) in partnership with the Alzheimer's Drug Discovery Foundation (ADDF), and with generous support by AstraZeneca, Janssen, Lilly, Merck, and Takeda, has awarded a $140,000 challenge grant to Blaine Roberts, PhD, Head of the Metalloproteomics Laboratory at The Florey Institute of Neuroscience and Mental Health in Australia. Dr. Roberts will be conducting research to validate a developmental blood test for Alzheimer’s disease.
The Alzheimer's Drug Discovery Foundation (ADDF) and the Children's Tumor Foundation (CTF) today announced a partnership to provide CTF's scientific network access to a virtual network of drug discovery experts and contract research organizations (CROs) through the ADDF ACCESS program. CTF's mission is to find effective treatments for the genetic disorder neurofibromatosis (NF), which can cause tumors to grow throughout the body and affects one in 3,000 people. Through the effective selection of CROs and use of their services, NF researchers may be able to accelerate their research and bring novel therapies to patients faster.
The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) announced today the recipients of their seventh annual partnership awards program to accelerate drug discovery for frontotemporal degeneration (FTD), a devastating form of dementia characterized by profound changes in behavior, personality, language and movement. Jeffrey Rothstein, MD, of Johns Hopkins University School of Medicine and Donald Lo, PhD, of Duke University Medical Center were each awarded $150,000 to conduct new research focused on developing novel drugs to treat FTD.
Research could lead to development of new therapies to treat a variety of mitochondrial diseases, including Autism, Alzheimer’s, Parkinson’s and Lou Gehrig’s disease
The Alzheimer’s Drug Discovery Foundation (ADDF) and the Foundation for Mitochondrial Medicine (FMM) announced today that they have awarded $200,000 in funding to James Bennett, M.D., Ph.D. to further research gene therapy of mitochondrial protein in the brains of mice with experimental Alzheimer’s disease. Bennett is studying rhTFAM, a novel human mitochondrial protein shown to increase mitochondrial function in cell and animal models. The protein has shown to restore memory function of aged mice while increasing mitochondrial function in brains, suggesting it has great potential to do the same in humans with impaired cognition and early Alzheimer’s disease.
The Alzheimer’s Drug Discovery Foundation of Canada (ADDF-Canada) and The W. Garfield Weston Foundation today announced a new funding collaboration to support a clinical trial investigating the potential for hypertension drugs to slow Alzheimer’s disease progression. The trial will be led by Dr. Sandra Black and the Toronto Dementia Research Alliance at the University of Toronto.